NCT04024813TerminatedPhase 2
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Gilead Sciences
- Enrollment
- 1
- Locations
- 10
- Primary Endpoint
- Relative Change in Baseline Serum Alkaline Phosphatase (AP) at Week 24
Study Overview
Brief Summary
The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
Dose masking
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Confirmed diagnosis of primary sclerosing cholangitis (PSC) based on any two of the following three criteria:
- •Historical evidence of an elevated alkaline phosphatase (AP) > upper limit of normal (ULN) from any prior laboratory result
- •Liver biopsy consistent with PSC
- •Abnormal cholangiography consistent with PSC as measured by magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), or percutaneous transhepatic cholangiography (PTC)
- •Individuals must have the following specific additional laboratory parameters measured by the Central Laboratory at Screening:
- •AP ≥ 1.5 × ULN and < 8 × ULN
- •Total bilirubin ≤ 2 × ULN
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN
- •Estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m^2
- •Platelets ≥ 140 × 10^3/µL
- •International Normalized Ratio (INR) ≤ 1.3 (in the absence of warfarin or other anticoagulant therapy)
- •Albumin ≥ 3.5 g/dL
- •Patients taking ursodeoxycholic acid (UDCA) will be allowed to enroll if meeting the following criteria:
- •Total daily dose of ≤ 20 mg/kg/day
- •A minimum of 6 months of stable treatment
- •Minimum of 12 weeks off treatment prior to Screening if UDCA is recently discontinued
Exclusion Criteria
- •Clinically significant acute or chronic liver disease of an etiology other than PSC
- •Patients with a diagnosis of overlapping autoimmune hepatitis (AIH) and PSC
- •Secondary or immunoglobulin G4 (IgG4) related sclerosing cholangitis
- •Small duct PSC
- •Presence of a cholangiocarcinoma on cholangiography or MRI at Screening as determined by the central radiologist and the principal investigator (PI) or medical monitor
- •Bile duct stent or percutaneous bile duct drain placement, or balloon dilatation procedure of a stricture within 12 weeks of Screening
- •History, evidence, or high suspicion of cholangiocarcinoma or other hepatobiliary malignancy based on imaging, screening laboratory values, and/or clinical symptoms
- •Presumptive or diagnosed acute cholangitis within 12 weeks of Screening and through Day 1
- •Evidence of compensated or decompensated cirrhosis based on histology, relevant medical complications, or laboratory parameters:
- •Historical liver biopsy demonstrating cirrhosis (eg, Ludwig Stage 4 or Ishak Stage 5)
- •Current or prior history of decompensated liver disease, including ascites, hepatic encephalopathy, variceal bleeding or other clinical conditions consistent with cirrhosis and/or portal hypertension,
- •Liver stiffness > 14.4 kPa by FibroScan, or
- •Combined low platelet count (< 140 × 10^3/µL ) with one of the following:
- •Serum albumin < 3.5 g/dL,
- •INR > 1.3 (not due to antithrombotic agent use), or
- •Total bilirubin > ULN
- •Prior or actively listed for liver transplantation
- •Prior exposure to seladelpar
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Arms & Interventions
Placebo (N=25)
Placebo Comparator
Placebo for the remainder of the study
Intervention: Placebo to match Seladelpar (Drug)
Seladelpar 5 mg (N=25)
Experimental
5 mg seladelpar daily for the remainder of the study
Intervention: Seladelpar (Drug)
Seladelpar 10 mg (N=25)
Experimental
10 mg seladelpar for the remainder of the study
Intervention: Seladelpar (Drug)
Seladepar 25 mg (N=25)
Experimental
25 mg seladelpar for the remainder of the study
Intervention: Seladelpar (Drug)
Outcomes
Primary Outcomes
Relative Change in Baseline Serum Alkaline Phosphatase (AP) at Week 24
Time Frame: Baseline, Week 24
Secondary Outcomes
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)(Up to Day 59)
- Incidence of Primary Sclerosing Cholangitis (PSC)-Related Symptoms or Procedures(Up to 24 weeks)
- Incidence of Hepatic Disease Progression Events(Up to 24 weeks)
Investigators
Study Sites (10)
Loading locations...
Similar Trials
Completed
Phase 3
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)Primary Biliary CholangitisNCT04620733CymaBay Therapeutics, Inc.193
Completed
Phase 2
Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of OnsetStrokeCerebral InfarctionNCT04486430Beijing Tiantan Hospital236
Completed
Phase 2
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory PolyneuropathyNeuropathic PainDistal Sensory PolyneuropathyNCT06568042Eli Lilly and Company558
Completed
Phase 2
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaChronic Spontaneous UrticariaNCT05368285Celldex Therapeutics208
Completed
Phase 3
A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.SchizophreniaNCT00111189Johnson & Johnson Pharmaceutical Research & Development, L.L.C.414